The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
Palbociclib has a unique mechanism of action which helps in delaying disease progression when co-administered with hormonal therapies
Multidisciplinary team expansion brings integrated medical, surgical, and radiation oncology services under one roof
FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4
Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy
The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options
Subscribe To Our Newsletter & Stay Updated
